GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $7.93 Consensus Price Target from Analysts

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have been given an average rating of “Moderate Buy” by the eleven brokerages that are currently covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $7.93.

A number of equities research analysts have issued reports on GDRX shares. Truist Financial decreased their price target on shares of GoodRx from $6.50 to $5.50 and set a “hold” rating for the company in a report on Thursday, April 10th. KeyCorp reduced their target price on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Citigroup reduced their target price on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research note on Friday, January 10th. Finally, Wells Fargo & Company reduced their target price on shares of GoodRx from $9.00 to $8.00 and set an “overweight” rating for the company in a research note on Friday, February 28th.

GoodRx Stock Down 1.1 %

GDRX stock opened at $4.63 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. GoodRx has a 52-week low of $3.82 and a 52-week high of $9.26. The company has a 50-day moving average of $4.57 and a two-hundred day moving average of $4.87. The stock has a market capitalization of $1.78 billion, a price-to-earnings ratio of -154.33, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Barclays PLC increased its holdings in shares of GoodRx by 1,316.1% during the third quarter. Barclays PLC now owns 140,113 shares of the company’s stock worth $973,000 after buying an additional 130,219 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of GoodRx by 6.3% during the third quarter. Geode Capital Management LLC now owns 982,729 shares of the company’s stock worth $6,823,000 after buying an additional 58,610 shares in the last quarter. Sanctuary Advisors LLC acquired a new stake in shares of GoodRx during the third quarter worth approximately $85,000. Franklin Resources Inc. acquired a new stake in shares of GoodRx during the third quarter worth approximately $5,675,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of GoodRx by 358.7% during the third quarter. JPMorgan Chase & Co. now owns 24,293 shares of the company’s stock worth $169,000 after buying an additional 18,997 shares in the last quarter. Institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.